
Spyglass Pharma, Inc. (NASDAQ:SGP – Free Report) – Research analysts at HC Wainwright lowered their FY2026 EPS estimates for Spyglass Pharma in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($2.76) for the year, down from their previous estimate of ($2.52). HC Wainwright has a “Buy” rating and a $43.00 price objective on the stock. The consensus estimate for Spyglass Pharma’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2026 earnings at ($0.75) EPS, Q1 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.64) EPS.
Several other research analysts have also weighed in on the company. Raymond James Financial assumed coverage on Spyglass Pharma in a report on Friday, August 14th. They set an “outperform” rating and a $39.00 target price on the stock. Wall Street Zen upgraded Spyglass Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings raised Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research report on Friday. Stifel Nicolaus raised their price target on Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. Finally, Citigroup lifted their price objective on Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 13th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.83.
Spyglass Pharma Stock Performance
SGP opened at $31.43 on Monday. Spyglass Pharma has a 12 month low of $17.06 and a 12 month high of $39.92. The company has a fifty day simple moving average of $28.90 and a 200 day simple moving average of $24.90.
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.07).
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in Spyglass Pharma in the 2nd quarter valued at approximately $533,000. Bank of America Corp DE acquired a new position in Spyglass Pharma during the 1st quarter worth approximately $726,000. The Manufacturers Life Insurance Company acquired a new position in Spyglass Pharma during the 1st quarter worth approximately $308,000. First Light Asset Management LLC acquired a new position in Spyglass Pharma during the 1st quarter worth approximately $9,716,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Spyglass Pharma during the 1st quarter worth approximately $6,478,000.
Spyglass Pharma Company Profile
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
Featured Articles
- Five stocks we like better than Spyglass Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
